Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer

Gynecologic Oncology

Volumn 114, Issue 1, 2009, Pages 42-47

  Lan, Chunyan ^a   Li, Yanfang ^a   Liu, Jihong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Chemotherapy; Fallopian tube cancer; Intraperitoneal therapy; Ovarian cancer; Primary peritoneal cancer

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ABDOMINAL PAIN; ADULT; AGE; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INJECTION SITE INFECTION; INJECTION SITE PAIN; INTESTINE PERFORATION; LEUKOPENIA; LIVER TOXICITY; LOW BACK PAIN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PERITONITIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; UTERINE TUBE CARCINOMA; VASCULAR ACCESS;

ADULT; AGED; COMBINED MODALITY THERAPY; FALLOPIAN TUBE NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; INFUSIONS, PARENTERAL; INJECTIONS, INTRAPERITONEAL; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PUNCTURES; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67349264871     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.03.034     Document Type: Article

References (26)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
2. O'Malley C.D., Cress R.D., Campleman S.L., and Leiserowitz G.S. Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study. Gynecol. Oncol. 91 (2003) 608-615
3. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 92 (2000) 699-708
4. Brun J.L., Feyler A., Chêne G., Saurel J., Brun G., and Hocké C. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol. Oncol. 78 (2000) 21-27
5. Markman M. Intraperitoneal drug delivery of antineoplastics. Drugs 61 (2001) 1057-1065
6. Fujiwara K., Armstrong D., Morgan M., and Markman M. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int. J. Gynecol. Cancer 17 (2007) 1-20
7. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335 (1996) 1950-1955
8. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 (2001) 1001-1007
9. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
10. Walker J.L., Armstrong D.K., Huang H.Q., Fowler J., Webster K., Burger R.A., et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol. Oncol. 100 (2006) 27-32
11. Marth C., Walker J.L., Barakat R.R., Casado A., Gadducci A., Miller B., et al. Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. Cancer 109 (2007) 645-649
12. Elit L., Oliver T.K., Covens A., Kwon J., Fung M.F., Hirte H.W., et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 109 (2007) 692-702
13. Fung-Kee-Fung M., Provencher D., Rosen B., Hoskins P., Rambout L., Oliver T., et al. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care. Gynecol. Oncol. 105 (2007) 747-756
14. Gadducci A., Carnino F., Chiara S., Brunetti I., Tanganelli L., Romanini A., et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol. Oncol. 76 (2000) 157-162
15. Yen M.S., Juang C.M., Lai C.R., Chao G.C., Ng H.T., and Yuan C.C. Intraperitoneal cisplatin-based chemotherapy versus. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int. J. Gynaecol. Obstet. 72 (2001) 55-60
16. Kirmani S., Braly P.S., McClay E.F., Saltzstein S.L., Plaxe S.C., Kim S., et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol. Oncol. 54 (1994) 338-344
17. Zhang M., Xie X., Lee A.H., Binns C.W., and Holman C.D. Body mass index in relation to ovarian cancer survival. Cancer Epidemiol. Biomark. Prev. 14 (2005) 1307-1310
18. The NCI common toxicity criteria version 3. Available from URL: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm 2006. Accessed on 02/10/09.
19. McClay E.F., Braly P.D., Kirmani S., Plaxe S.C., Kim S., McClay M.E., et al. A phase II trial of intraperitoneal high-dose carboplatin and etoposide with granulocyte macrophage-colony stimulating factor support in patients with ovarian carcinoma. Am. J. Clin. Oncol. 18 (1995) 23-26
20. Markman M., Brady M.F., Spirtos N.M., Hanjani P., and Rubin S.C. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J. Clin. Oncol. 16 (1998) 2620-2624
21. Barakat R.R., Sabbatini P., Bhaskaran D., Revzin M., Smith A., Venkatraman E., et al. Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J. Clin. Oncol. 20 (2002) 694-698
22. Fujiwara K., Sakuragi N., Suzuki S., Yoshida N., Maehata K., Nishiya M., et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol. Oncol. 90 (2003) 637-643
23. Makhija S., Leitao M., Sabbatini P., Bellin N., Almadrones L., Leon L., et al. Complications associated with intraperitoneal chemotherapy catheters. Gynecol. Oncol. 81 (2001) 77-81
24. Davidson S.A., Rubin S.C., Markman M., Jones W.B., Hakes T.B., Reichman B., et al. Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol. Oncol. 41 (1991) 101-106
25. Fujiwara K., Suzuki S., Ishikawa H., Oda T., Aotani E., and Kohno I. Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube. Int. J. Gynecol. Cancer 15 (2005) 426-431
26. Black D., Levine D.A., Nicoll L., Chou J.F., Iasonos A., Brown C.L., et al. Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. Gynecol. Oncol. 109 (2008) 39-42